Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A novel t(5;7)(q31;q21/CDK6::IL3 in immature T-cell acute lymphoblastic leukemia with IL3 overexpression and reactive eosinophilia [SNP]

ABSTRACT: IL3 expression and reactive eosinophils

ORGANISM(S): Homo sapiens

PROVIDER: GSE211170 | GEO | 2025/08/11

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

A novel t(5;7)(q31;q21/CDK6::IL3 in immature T-cell acute lymphoblastic leukemia with IL3 overexpression and reactive eosinophilia [WTE]

Project description:IL3 expression and reactive eosinophils

2025-08-11 | GSE211476 | GEO

A novel t(5 7)(q31 q21/CDK6::IL3 in immature T-cell acute lymphoblastic leukemia with IL3 overexpression and reactive eosinophilia [SNP]

Project description:A novel t(5 7)(q31 q21/CDK6::IL3 in immature T-cell acute lymphoblastic leukemia with IL3 overexpression and reactive eosinophilia [SNP]

| PRJNA869310 | ENA

A novel t(5 7)(q31 q21/CDK6::IL3 in immature T-cell acute lymphoblastic leukemia with IL3 overexpression and reactive eosinophilia

Project description:A novel t(5 7)(q31 q21/CDK6::IL3 in immature T-cell acute lymphoblastic leukemia with IL3 overexpression and reactive eosinophilia

| PRJNA870479 | ENA

A novel t(5 7)(q31 q21/CDK6::IL3 in immature T-cell acute lymphoblastic leukemia with IL3 overexpression and reactive eosinophilia [WTE]

Project description:A novel t(5 7)(q31 q21/CDK6::IL3 in immature T-cell acute lymphoblastic leukemia with IL3 overexpression and reactive eosinophilia [WTE]

| PRJNA870485 | ENA

A novel t(5;7)(q31;q21/CDK6::IL3 in immature T-cell acute lymphoblastic leukemia with IL3 overexpression and reactive eosinophilia

Project description:This SuperSeries is composed of the SubSeries listed below.

2025-08-11 | GSE211484 | GEO

A Novel t(5;7)(q31;q21)/CDK6::IL3 in Immature T-cell Acute Lymphoblastic Leukemia With IL3 Expression and Eosinophilia.

Project description: Not available

| S-EPMC9584195 | biostudies-literature

CCL11/CCR3-dependent eosinophilia alleviates malignant pleural effusions and improves prognosis

Project description:The role of eosinophils in the development and progression of malignant pleural effusion (MPE) remains unclear. However, MPE is a frequently occurring manifestation of advanced cancer and is often associated with a poor prognosis. While current treatment options for MPE can provide palliative care, alternative therapies are urgently needed. To investigate this role, eosinophil counts were determined using flow cytometry and immunofluorescence. Eosinophil-deficient mice (Eos-null) and Cd3δ -promoter Il5 transgenic (Il5 Tg) mice were subjected to a mouse model of MPE. Eosinophils were isolated by magnetic-activated cell sorting (MACS) and fluorescence-activated cell sorting (FACS), and their transcriptional profile was obtained by RNA sequencing. Finally, we evaluated the effects of the C-C motif chemokine ligand 11 (CCL11) and a C-C motif chemokine receptor 3 (CCR3) axis on MPE pathology using recombinant mouse CCL11 and a CCR3 inhibitor. In humans, eosinophil counts were increased in MPE and negatively correlated with the LENT score. In animal models, eosinophils were rapidly recruited to the pleural cavity when challenged with tumor cells. Interestingly, eosinophil deficiency worsened MPE, while an increase in eosinophils through various methods improved MPE. Furthermore, the recruitment of eosinophils may be influenced by the CCL11-CCR3 axis. Taken together, the study highlights the protective role of eosinophils against MPE formation, indicating their potential as a therapeutic strategy. Moreover, the CCL11-CCR3 axis may be a viable target for MPE treatment.

2024-08-01 | GSE245575 | GEO

Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia.

Project description:Ph+ ALL is a poor-prognosis leukemia subtype driven by the BCR-ABL1 oncogene, either the p190- or the p210-BCR/ABL isoform in a 70:30 ratio. Tyrosine Kinase inhibitors (TKIs) are the drugs of choice in the therapy of Ph+ ALL. In combination with standard chemotherapy, TKIs have markedly improved the outcome of Ph+ ALL, in particular if this treatment is followed by bone marrow transplantation. However, resistance to TKIs develops with high frequency, causing leukemia relapse that results in <5-year overall survival. Thus, new therapies are needed to address relapsed/TKI-resistant Ph+ ALL. We have shown that expression of cell cycle regulatory kinase CDK6, but not of the highly related CDK4 kinase, is required for the proliferation and survival of Ph+ ALL cells. Comparison of leukemia suppression induced by treatment with the clinically-approved dual CDK4/6 inhibitor palbociclib versus CDK6 silencing revealed that the latter treatment was markedly more effective, probably reflecting inhibition of CDK6 kinase-independent effects. Thus, we developed CDK4/6-targeted proteolysis-targeting chimeras (PROTACs) that preferentially degrade CDK6 over CDK4. One compound termed PROTAC YX-2-107, which degrades CDK6 by recruiting the Cereblon ubiquitin ligase, markedly suppressed leukemia burden in mice injected with de novo or TKI-resistant Ph+ ALL. The effect of PROTAC YX-2-107 was comparable or superior to that of palbociclib. The development of CDK6-selective PROTACs represents an effective strategy to exploit the "CDK6 dependence" of Ph+ ALL cells while sparing a high proportion of normal hematopoietic progenitors that depend on both CDK6 and CDK6 for their survival. In combination with other agents, CDK6-selective PROTACs may be valuable components of chemotherapy-free protocols for the therapy of Ph+ ALL and other CDK6-dependent hematological malignancies.

| S-EPMC8467343 | biostudies-literature

B cell-stromal cell cross talk drives mesenteric lymph node eosinophilia during intestinal helminth infection

Project description:We hypothesised that eosinophil activation and gene expression were linked to their interaction with the activated stroma within the lymph node. However, the role of eosinophil stromal crosstalk and how this modulate eosinophil function is unknown. To directly assess this hypothesis, we activated lymph node derived stromal cells using an agonist antibody for LTR (Clone 4H8WH2). Considering eosinophils have long been associated with providing B cell proliferative and survival factors, we mimicked a cell-based activation model using purified naïve B cells given that B cell interactions with stroma can produce factors that can regulate eosinophil activation and migration. B cell-based activation as well as agonist antibody-based activation resulted in an activated stromal phenotype and were later used for co-culture with bone marrow-derived eosinophils. After 8 hours of co-culture with activated stroma, the eosinophils were purified, and bulk RNA sequencing was performed to identify global changes in their transcriptomes.

2024-08-12 | GSE272167 | GEO

DNA accessibility in reactive and non-reactive CMV specific CD8+ lymphocytes

Project description:DNA accessibility in reactive and non-reactive CMV specific CD8+ lymphocytes

| PRJNA413763 | ENA